I 131 Mini
Loading...I 131 Mini Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
There is currently no warning information available for this product. We apologize for any inconvenience.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
There is currently no usage information available for this product. We apologize for any inconvenience.
History
There is currently no drug history available for this drug.
Other Information
Sodium Iodide I-131 (NaI-131) for therapeutic use is supplied for oral administration in small opaque white gelatin capsules, inside a blue and clear outer capsule. Each I-131 mini capsule is available in strengths ranging from (0.1 – 150 mCi) at the time of calibration. Iodine 131 decays by beta emission and associated gamma emission with a physical half-life of 8.04 days.
Sodium Iodide I-131 Mini Capsules are compounded by absorbing a solution of carrier-free sodium iodide I-131 into inert filler. The iodine 131 utilized in the preparation of the capsules contains not less than 99% Iodine-131 at the time of calibration.
Gelatin capsules are compounded per prescription requirements using high specific concentration I-131, allowing higher iodine activity in a small easy to swallow high activity capsule size. Capsules are formulated to rapidly dissolve in saline solution, to allow use for oral solution administration when clinically necessary.
Sources
I 131 Mini Manufacturers
-
Anazaohealth Corporation
![I 131 Mini Capsule [Anazaohealth Corporation]](/wp-content/themes/bootstrap/assets/img/loading2.gif)
I 131 Mini | Anazaohealth Corporation
Anti-thyroid therapy of a severely hyperthyroid patient is usually discontinued three to four days before administration of radioiodide. For hyperthyroidism, the usual dose range is 4 to 10 mCi. Toxic nodular goiter and other special situations will require the use of larger doses. For thyroid carcinoma, 50 mCi is the usual dose for ablation of normal thyroid tissue, and 100 to 150 mCi is the usual subsequent therapeutic dose. Waterproof gloves should be used during the entire handling and administration procedure. Adequate shielding must be maintained.
Login To Your Free Account